Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CTI Makes Over Zevalin As Front-Line NHL Therapy Booster

This article was originally published in The Pink Sheet Daily

Executive Summary

Drug is on FDA fast track and new partner is on board, but firm must still clear roadblocks to win acceptance in the marketplace.
Advertisement

Related Content

CTI Bags Cash, Turns Its Back On Zevalin
CTI Bags Cash, Turns Its Back On Zevalin
Broader Zevalin NHL Label: 18 Times More Use?
CTI Plans Label Expansion For Zevalin After Acquiring The NHL Drug From Biogen
CTI Plans Label Expansion For Zevalin After Acquiring The NHL Drug From Biogen

Topics

Advertisement
UsernamePublicRestriction

Register

PS067174

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel